Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Stiolto Respimat for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Drug Name (Brand / Generic)

Stiolto Respimat (tiotropium bromide and olodaterol)

Developed by

Boehringer Ingelheim Pharmaceuticals

Therapy Class

Anti-cholinergic

Product Description

Long-acting beta2-adrenergic agonist (LABA)

Current Indication

Chronic Obstructive Pulmonary Disease (COPD)

Market Sector

Respiratory

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top